Pregnancy, MAT and Addiction

Size: px
Start display at page:

Download "Pregnancy, MAT and Addiction"

Transcription

1 Pregnancy, MAT and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine William Morrone, DO, MPH, DABAM Covenant Hospital OB consultant 1

2 Author credit Today I will present slides from my friend and teacher: Carl CHRISTENSEN, MD, PhD Carl and I have been doing Pregnancy / Addiction for 10 years. We share often and I give him 100% credit. 2

3 Educational Objectives At the conclusion of this activity participants should be able to: Understand the current neurobiological basis for addictive disorders. Be familiar with the three current FDA approved medications for Opioid Use Disorders Be aware of the current recommendations for treatment of Opioid Use Disorder during Pregnancy Review the use of short acting naloxone for reversal of opioid overdose. 3

4 WHY TALK ABOUT THIS? Addiction and Pregnancy 4 4

5 WHY TALK ABOUT THIS? Addiction and Pregnancy 5 5

6 WHY TALK ABOUTTHIS? N.A.S. in Southeastern Mich Addiction and Pregnancy 6 6

7 What is Addiction? Physiology of Addiction 7 7

8 The Nucleus Accumbens: Craving and Reward Physiology of Addiction 8 8

9 VTA: the gas tank : supplies dopamine to the Nucleus Accumbens Physiology of Addiction 9 9

10 Frontal Cortex: Impulse Control Physiology of Addiction 10 10

11 What is Addiction? Addiction is not a problem of drug WITHDRAWAL

12 What is Addiction? It is a problem of: o CRAVING o LOSS OF CONTROL o COMPULSIVE USE o USE DESPITE CONSEQUENCES 12 12

13 13 13

14 14 14

15 15 15

16 16 16

17 Frontal Cortex and Addiction High flow Healthy Control Cocaine-dependent Gottschalk, 2001, Am J Psychiatry Physiology of Addiction 17 Low flow 17

18 Frontal Cortex and Addiction Non users High blood flow Cocaine users, 10 days sober Cocaine Users, 100 days sober Low blood flow Physiology of Addiction 18 18

19 Frontal Cortex and Addiction Non users High blood flow Cocaine users, 10 days sober Cocaine Users, 100 days sober Low blood flow Physiology of Addiction 19 19

20 Frontal Cortex and Addiction Non users High blood flow Cocaine users, 10 days sober Cocaine Users, 100 days sober Physiology of Addiction 20 Low blood flow 20

21 CONTROL [C-11]d-threo-methylphenidate How Long to recover from Methamphetamine? Normal Control Methamphetamine Abuser (1 month abstinent) high low Volkow et al., J. Neuroscience, Methamphetamine Abuser (14 months abstinent) 21

22 [C-11]d-threo-methylphenidate 30 days abstinent Normal Control high Methamphetamine Abuser (1 month abstinent) low Volkow et al., J. Neuroscience, Methamphetamine Abuser (14 months abstinent) 22

23 [C-11]d-threo-methylphenidate 14 months + to recover from Methamphetamine!!! Normal Control Methamphetamine Abuser (1 month abstinent) high low Volkow et al., J. Neuroscience, Methamphetamine Abuser (14 months abstinent) 23

24 Treatment of Opioid Use Disorder Medication Assisted Treatment Agonists Antagonists* (MAT) Level I: outpatient treatment +/- MAT * Not currently used in Pregnancy 24 24

25 Agonists vs. Antagonists Drug Type Analogy Methadone Full Agonist High Octane Buprenorphine Partial Agonist Low Octane Naltrexone Antagonist Water 25 25

26 BOTTOM LINE: In both controlled and retrospective studies, the success rate for most medications is between 40 and 60% (one to two years). When patients come off the medication, they relapse. Relapse may be associated with an increased chance of overdose and death. Physiology of Addiction 26 26

27 Benefits of Methadone Salsitz, ASAM, 2012 Reduction in death rates (Grondblah, 1990) Reduction in IVDU (Ball & Ross, 1991) Reduction in # of crime days (Ball & Ross) Reduced HIV seroconversion / HCV conversion IMPROVED OUTCOME AFTER INCARCERATION 27

28 Ball 1988: reduction in IVDU ORT: yes or no??? 28 28

29 Ball 1988: reduction in IVDU ORT: yes or no??? 29 29

30 Ball 1988: resumption of IVDU! ORT: yes or no??? 30 30

31 Ball 1988: resumption of IVDU! ORT: yes or no??? 31 31

32 Buprenorphine A partial opiate agonist (less potent) Less analgesic effect Less respiratory depression <100 documented deaths in the U.S. (Soyka); PER YEAR WITH METHADONE Treats both pain and opiate dependency Different formulations are approved Addiction and Pregnancy 32 32

33 Buprenorphine Available in 3 branded forms: Generic buprenorphine (Subutex ): sublingual OFF MARKET: Medicaid may not cover generic due to concerns about diversion. Bunavail : sublingual buprenorphine + naloxone (Narcan ): prevents IV use* Suboxone : sublingual buprenorphine + naloxone (Narcan ): prevents IV use* Zubsolv : ditto ANY of these will precipitate sudden withdrawal: only give when patient is going INTO withdrawal! * not FDA approved for pain Addiction and Pregnancy 33 33

34 Buprenorphine Formulations approved for PAIN: Buprenex : parenteral, used in the hospital setting. Butrans : weekly patch, 10 to 20 mcg/hr Belbuca : buccal film from mcg/24 hr. Addiction and Pregnancy 34 34

35 What Formulation Should You Use? Generic buprenorphine avoids naloxone. It is more susceptible to diversion Use whatever their insurance will pay for!! 35 35

36 Buprenorphine long-term follow up: Fiellin,

37 Concerns about buprenorphine It can be abused (mostly for withdrawal) It is unsafe when combined with sedatives & alcohol. It is an opioid. Relapse rates after detox exceed 90%. (Weiss, 2011) 37 37

38 Vivitrol (injectable naltrexone) for opioid dependence This medication is not currently used during pregnancy; but may be used following delivery. 38

39 Addiction Tx in Russia Kupitsky et al; Lancet 2011; 377:

40 Vivitrol: abstinence 40

41 Vivitrol: craving 41

42 Vivitrol: concerns As with methadone and buprenorphine, when the medication is stopped, relapse may lead to death due to lack of tolerance. Pain management after injectable naltrexone is challenging and may require hospitalization. 42

43 Doc, when can I get off this sh*t medication? Can you detox? 43 43

44 Luty women underwent detox during pregnancy 40 successfully detoxed. No adverse fetal effects documented Luty et al, J Sub Abuse Treat 24 (2003); ORT: yes or no??? 44 44

45 Detoxing During Pregnancy? Luty 2003 Luty women underwent detox during pregnancy 40 successfully detoxed. No adverse fetal effects documented But: only 1/101 patients documented to be abstinent at time of delivery! Luty et al, J Sub Abuse Treat 24 (2003); ORT: yes or no??? 45 45

46 Maintenance vs. Detox? Kakko et al heroin users were started on buprenorphine/naloxone. 20 were detoxed off and offered counseling. 20 were kept on buprenorphine and offered counseling. A year later. ORT: yes or no??? 46 46

47 47 47 OR T:

48 48 48 OR T:

49 Can you taper off buprenorphine without relapse? 49

50 Buprenorphine in opioid dependence 654 patients enroll on buprenorphine for 2 weeks. 50% stay abstinent. They are tapered off and over 90% relapse. 360 remain, they go back on buprenorphine for 12 weeks, 50% stay abstinent. They taper off and 90+% relapse. Moral of the story: medications work as long as you take them. 59

51 Opioid Detox During Pregnancy Bell et al, AJOG 2016; 215: 374.e1-6 Fetal death during pregnancy is rare. Patients can be successfully and safely detoxed. The lowest neonatal abstinence rates are seen with incarcerated patients (19%) and inpatient detox with intensive outpatient treatment (17%) Worst results are inpatient detox without IOP (70%) and buprenorphine outpatient detox (31%) 51

52 Treatment of Opioid Dependence During Pregnancy 52

53 METHADONE the gold standard Was only approved for use for addiction in 1965; Dr. James Wardell started in Detroit in TIP 40: methadone is (was) the preferred treatment in pregnancy. Buprenorphine should be offered ONLY if methadone not available or patient refuses methadone. Buprenorphine was considered experimental. Jones and Johnson: small studies showed promise

54 Maternal Opioid Treatment: Human Experimental Research (MOTHER) 54

55 :NEJM 2010; 363: Addiction and Pregnancy 55 55

56 MOTHER STUDY Double blinded, RCT Methadone vs. buprenorphine Contingency management (financial incentives $$ $$) CBT (cognitive behavioral tx) Transportation, etc. NO polysubstance dependence x tobacco! Addiction and Pregnancy 56 56

57 MOTHER STUDY Patients already on methadone are admitted to research unit for detox. 6 mg MS/mg methadone (4 divided doses) Rescue doses prn Kept until stabilized THIS IS NOT FEASIBLE IN CLINICAL PRACTICE!!!!!!!!! Randomized to study meds on L & D Addiction and Pregnancy 57 57

58 Sites Johns Hopkins, Baltimore MD T. Jefferson Univ., Philadelphia, PA Women & Infants, Providence RI Vanderbilt UMC, Nashville, TN St. Joseph s Hlth Ctr. Toronto, Canada Wayne State Univ., Detroit, Michigan University of VT, Burlington, VT Addiction Clinic Vienna, Au Addiction and Pregnancy 58 58

59 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 59 59

60 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 60 60

61 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 61 61

62 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 62 62

63 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 63 63

64 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 64 64

65 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 65 65

66 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 Addiction and Pregnancy 66 66

67 MOTHER study. Buprenorphine exposed neonates exhibited fewer stress-abstinence signs, were less excitable less hypertonia better self-regulation and required less handling than methadoneexposed neonates. Jones Finnegan & Kaltenbach Drugs

68 Who should NOT go on buprenorphine? Patients who are: Already on methadone (>35 mg) Active hepatitis C (high LFTs) Unable to engage in treatment Taking benzos Plan on mixing bup with their opiates Are diverting Can t get insurance coverage Addiction and Pregnancy 68 68

69 How do you start buprenorphine? LFT, UDS, informed consent If GA > 24 weeks: monitor on L&D Short acting opioids: 8 to 12 hrs abstinence or moderate withdrawal sx Start buprenorphine DC on 8 to 16 mg bupx sublingual Addiction and Pregnancy 69 69

70 Buprenorphine-->Methadone? NOT necessary! Can continue buprenorphine Risk of NAS is decreased (severity and duration) Addiction and Pregnancy 70 70

71 Methadone à Buprenorphine? Methadone: Has a LONG half life MOTHER study dropouts were due to attempts to convert high dose methadone to buprenorphine Current expert opinion is to limit to patients on mg. Safest course may be to remain on methadone. Addiction and Pregnancy 71 71

72 Current Management: Eleonore Hutzel Recovery Center, Detroit Mich Patients who present on SHORT acting opioids: buprenorphine Patients who present on long acting opioids or methadone: methadone Benzodiazepine use must stop immediately or will be referred to methadone. Failure to remain abstinent: refer to methadone

73 Labor/Surgery in Pregnant Patients on Buprenorphine: Options Planned delivery: convert to short acting opiates and back again Stop buprenorphine, start short acting opioids at any time. Resume buprenorphine after 12 hrs abstinence No opiates, rely on epidural (vag delivery only) Continue treatment with Buprenex SL Buprenorphine/Buprenex have been used postoperatively Addiction and Pregnancy 73 73

74 Epidural Management Middle East J Anesthesiol 2013 Oct; 22(3):

75 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Don t discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, EHRC when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! Addiction and Pregnancy 75 75

76 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Don t discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, EHRC when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! Addiction and Pregnancy 76 76

77 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Don t discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, EHRC when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! Addiction and Pregnancy 77 77

78 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Don t discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, EHRC when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! Addiction and Pregnancy 78 78

79 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Don t discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, EHRC when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! Addiction and Pregnancy 79 79

80 The Opioid Epidemic & Naloxone (Narcan ) Rescue Developed for Families Against Narcotics 80

81 Naltrexone vs. Naloxone Naltrexone Oral (Rivea ) or IM (Vivitrol ) Slow onset Long acting (hours to weeks) Tightest binding to brain Used for PREVENTION of overdose (FDA) Naloxone IV, IM, SC or IN (Narcan, Evzio ) Rapid Onset Short acting (minutes) Less tightly bound Used for TREATMENT of overdose (FDA) 81 81

82 What Does Narcan NOT Do? It will not reverse an overdose from alcohol, sedatives (Benzodiazepines such as Xanax, Valium and Klonopin), muscle relaxants, or stimulants like Cocaine or Amphetamines. If there is more than one drug involved (usually Benzodiazepines and Opioids), it may partially revive the patient until EMS arrives. 82

83 Naloxone formulations: 83 83

84 Who is at Greatest Risk? Abstinence > 2 weeks: treatment; jail; relapse. Discontinuing MAT: methadone; buprenorphine; Vivitrol (naltrexone). (Volkow 2014: 50% decr in OD deaths with MAT) Mixing opioids with sedatives: alcohol, benzodiazepines, muscle relaxers FENTANYL 84 84

85 OD deaths: heroin and Fentanyl: Washtenaw Co. 75% DUE TO HEROIN +/- FENTANYL; 25% DUE TO PRESCRIPTION PILLS 28 (heroin) 21 (fentanyl + heroin) 12 (pills) (25%) 49 (total) 85

86 Fentanyl on Urine Drug Screen Pregnant Patient 86 86

87 How To Do A Naloxone Rescue (youtube.com -> ccmdphd) Make Sure They are Not Breathing or risk of failure (always) Call 911 Do Rescue Breaths (not compressions) Give Naloxone Resume Rescue Breaths Repeat Naloxone every 2-3 mins 87 87

Pregnancy and Addiction

Pregnancy and Addiction Pregnancy and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine November 16, 2016 1 Educational Objectives At the

More information

Pregnancy and Addiction 1

Pregnancy and Addiction 1 Disclaimers Addiction and Pregnancy 2017 Carl Christensen, MD, PhD, D-FASAM Clinical Assoc Prof, Psychiatry and OB/Gyn, Wayne State Univ School of Med, Detroit Mi Medical Director, Mich Health Professional

More information

Who is Behind the Opioid Epidemic?

Who is Behind the Opioid Epidemic? Safe and Effective Management of Pain and Addiction CARL CHRISTENSEN, MD PHD MEDICAL DIRECTOR, DAWN FARM CLINICAL ASSOCIATE PROFESSOR, WSU SCHOOL OF MEDICINE WWW.CHRISTENSENRECOVERY.COM Tonight s Talk:

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

Does Treatment Work? Disclaimers. What is Addiction? Lack of Willpower? Addiction and Recovery News. Physiologic Dependence: Tolerance and Withdrawal

Does Treatment Work? Disclaimers. What is Addiction? Lack of Willpower? Addiction and Recovery News. Physiologic Dependence: Tolerance and Withdrawal Disclaimers Does Treatment Work? Carl Christensen MD PhD, FASAM Clinical Associate Professor, WSU School of Medicine Medical Director, Dawn Farm Medical Director, Mich Health Recovery Prof Program n n

More information

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O. Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Does Treatment Work? Disclaimers. What is Recovery? Does Treatment Work? 5/16/17. To Get This PowerPoint and copies of the Articles.

Does Treatment Work? Disclaimers. What is Recovery? Does Treatment Work? 5/16/17. To Get This PowerPoint and copies of the Articles. Does Treatment Work? Carl Christensen MD PhD, FASAM Medical Director, Dawn Farm Clinical Associate Professor, WSU School of Medicine Medical Director, Mich Health Recovery Prof Program Advisory Board,

More information

Buprenorphine as a Treatment Option for Opioid Use Disorder

Buprenorphine as a Treatment Option for Opioid Use Disorder Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital

More information

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University

More information

Anyone Can Become Addicted. Anyone.

Anyone Can Become Addicted. Anyone. Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Medication-Assisted Treatment (MAT) Overview

Medication-Assisted Treatment (MAT) Overview Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for

More information

Topics of today s training

Topics of today s training Extended Release Naltrexone Vivitrol Christopher J Davis D.O. CAADC, FASAM Medical Director, Brightwater Landing Medical Director, Pyramid Healthcare Diplomate of The American Board of Addition Medicine

More information

Discover the Hope: Opiate Treatment and Recovery

Discover the Hope: Opiate Treatment and Recovery Discover the Hope: Opiate Treatment and Recovery The Continued Struggle to Find and Implement Best Practices Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,

More information

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

The role of behavioral interventions in buprenorphine treatment of opioid use disorders

The role of behavioral interventions in buprenorphine treatment of opioid use disorders The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies

More information

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH IF THESE MOMS REALLY CARED ABOUT THEIR BABIES, THEY WOULD JUST QUIT Those who can quit, often do Addiction

More information

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose

More information

Buprenorphine pharmacology

Buprenorphine pharmacology Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely

More information

Medication Assisted Treatment of Substance Use Disorders

Medication Assisted Treatment of Substance Use Disorders 3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard

More information

7/7/2016 Journal of the American Medical Association,

7/7/2016 Journal of the American Medical Association, 1 2 Journal of the American Medical Association, 2008 3 The Clinical Trial 152 Adolescents and Young Adults (Age 15 to 21) randomly assigned to either; 1. 2 weeks of Buprenorphine detox 2. 12 weeks of

More information

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report

More information

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone) 9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a Appendix 1. Literature Search Databases Years Search Terms Pubmed 01/1966 1. Analgesics, Opioid a / or Opioid-related Disorders a / PsycINFO EMBASE Cochrane 09/2016 or Heroin a / or Heroin Dependence a

More information

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of

More information

Understanding and Combating the Heroin Epidemic

Understanding and Combating the Heroin Epidemic Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the

More information

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

Identification and Treatment of Opioid Use Disorders in Primary Care Settings Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine

More information

Medication Assisted Treatment

Medication Assisted Treatment Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral

More information

Medication for the Treatment of Addiction (MAT)

Medication for the Treatment of Addiction (MAT) Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication

More information

Vivitrol Drug Court and Medication Assisted Treatment

Vivitrol Drug Court and Medication Assisted Treatment Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment

More information

Methadone and Pregnancy

Methadone and Pregnancy Methadone and Pregnancy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Charissa Patricelli, MD, CCFP, ABAM Clinical Associate Professor, Dept. of Family Practice UBC American Board of Addiction Medicine

More information

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home

More information

Vivitrol Vs. Suboxone

Vivitrol Vs. Suboxone Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak

More information

USE OF BUPRENORPHINE FOR CHRONIC PAIN

USE OF BUPRENORPHINE FOR CHRONIC PAIN Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND

More information

Medication-assisted opioid addiction treatments: OB/GYN

Medication-assisted opioid addiction treatments: OB/GYN 5/13/16se Medication-assisted opioid addiction treatments: OB/GYN In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex, and a buprenorphine/naloxone

More information

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS LEO O. LANOIE, MD, MPH, FCFP, CCSAM, ABAM, FISAM, MRO Dr. Leo Lanoie, 2017 DISCLAIMER In the past year I have accepted funds from Purdue for speaking OPIOID

More information

Treating Opioid Use Disorders: An Update for Counselors and Other Providers

Treating Opioid Use Disorders: An Update for Counselors and Other Providers Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL

More information

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a

More information

MAT in the Corrections Setting

MAT in the Corrections Setting MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on

More information

Opioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center

Opioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center Opioid Use Disorder- Pregnancy Principles and Myths Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center History of NAS/NOWS Prior to 1875 infants not thought to be affected Congenital Morphinism

More information

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for

More information

Latest Press Release. How much for 30 mg adderall

Latest Press Release. How much for 30 mg adderall corp@stantec.com Latest Press Release How much for 30 mg adderall S 14-2-2008 Hi my name is Rachel i have been on suboxone for almost a year as of OCT 1st, and I have become the person I guess I am to

More information

Management of Opioid Use Disorder in Primary Care

Management of Opioid Use Disorder in Primary Care 1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,

More information

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction

More information

Opioid Dependence During Pregnancy: Balancing Risk/Benefit

Opioid Dependence During Pregnancy: Balancing Risk/Benefit Opioid Dependence During Pregnancy: Balancing Risk/Benefit Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology Vanderbilt University Acknowledgement: R01DA015713 Conflicts: None Outline I. Epidemiology

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Steven Prakken MD Director Medical Pain Service Duke Pain Medicine

Steven Prakken MD Director Medical Pain Service Duke Pain Medicine Steven Prakken MD Director Medical Pain Service Duke Pain Medicine Misuse Abuse Addiction Total Pain Population Webster LR, Webster RM. Pain Med. 2005;6(6):432-442. DSM IV Abuse defined as 2 elements

More information

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are

More information

Opioid Use Disorders &Medication Treatment

Opioid Use Disorders &Medication Treatment Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review

More information

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical

More information

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers

More information

Opioid dependence and buprenorphine treatment

Opioid dependence and buprenorphine treatment Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions

More information

Understanding Opioid Addiction and. Medication Assisted Treatment for. Families in the Child Welfare System

Understanding Opioid Addiction and. Medication Assisted Treatment for. Families in the Child Welfare System Understanding Opioid Addiction and Medication Assisted Treatment for Families in the Child Welfare System Medicine Jason B. Fields, MD, FASAM Associate Medical Director, DACCO Behavioral Health, Inc. President

More information

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

Medication-Assisted Treatment (MAT) for Opioid Use Disorders Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following

More information

Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis

Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Sponsored by the Florida Alcohol and Drug Abuse Association

More information

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for

More information

The Opioid Crisis: What Can Physicians Do About It?

The Opioid Crisis: What Can Physicians Do About It? The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures

More information

STARTING SUBOXONE IN PRIMARY CARE

STARTING SUBOXONE IN PRIMARY CARE Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences STARTING SUBOXONE IN PRIMARY CARE MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Review evidence of how to

More information

Understanding Medication in Addiction Treatment for Drug Court Participants

Understanding Medication in Addiction Treatment for Drug Court Participants Understanding Medication in Addiction Treatment for Drug Court Participants Introduction This pocket guide is for drug court participants who may be prescribed or considering medication as a part of addiction

More information

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop

More information

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance

More information

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Thank you, Chairman Rogers, for holding this important Summit and helping to bring attention

More information

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers

More information

Overdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine.

Overdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Part B 2 3 4 Overdose Treatment Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Specifically used to counteract lifethreatening depression of

More information

HARM REDUCTION & TREATMENT. Devin Reaves MSW

HARM REDUCTION & TREATMENT. Devin Reaves MSW HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education

More information

The Importance of Psychological Treatment and Behavioral Support

The Importance of Psychological Treatment and Behavioral Support The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding

More information

Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement

Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement TANNER NISSLY DO, BOB LEVY MD FASAM, MICHELE MANDRICH MSW, CMPE AS YOU ENTER, PLEASE SET UP TO PARTICIPATE IN OUR POLL EVERYWHERE

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

The Latest Prescription Trends for Controlled Prescription Drugs

The Latest Prescription Trends for Controlled Prescription Drugs The Latest Prescription Trends for Controlled Prescription Drugs September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner

More information

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016 What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)

More information

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING

More information

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine Opioid Use Disorders and Pregnancy Marcela Smid, MD Maternal-Fetal Medicine UNIVERSITY OF UTAH HEALTH, 2017 OBJECTIVES Definitions Epidemiology Pharmacology Effects on pregnancy Screening Treatment CARE

More information

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand

More information

Supported by the Indiana Public Health Training Center. Welcome We will begin shortly

Supported by the Indiana Public Health Training Center. Welcome We will begin shortly Supported by the Indiana Public Health Training Center Welcome We will begin shortly Public Health Insights and Innovations Self-Claim Attendance Please text code 42223 to 317-671-8998 to record your attendance

More information

Opioid Dependence and Buprenorphine Management

Opioid Dependence and Buprenorphine Management Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale

More information

Extended-Release Naltrexone for Opioid Relapse Prevention

Extended-Release Naltrexone for Opioid Relapse Prevention Extended-Release Naltrexone for Opioid Relapse Prevention 1.NYU SOM; Bellevue Hospital Center 2.Brown Univ. 3. Friends Research Institute 4. Columbia Univ. 5. Univ. Pennsylvania 6. Univ. Virginia Funding:

More information

Opioid Use Disorder Treatment Initiation in Diverse Settings

Opioid Use Disorder Treatment Initiation in Diverse Settings Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures

More information

Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities

Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities Jeanette M. Tetrault, MD FACP FASAM Associate Professor of Medicine Program

More information

UNDERSTANDING THE DISEASE OF ADDICTION by Suresh Joseph

UNDERSTANDING THE DISEASE OF ADDICTION by Suresh Joseph UNDERSTANDING THE DISEASE OF ADDICTION by Suresh Joseph Summary of Presentation Addiction as a disease Medical harm of substance use Treatment models for substance dependence Local support services for

More information

Noel Schenk MD. Davis Behavioral Health

Noel Schenk MD. Davis Behavioral Health Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by

More information

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to

More information

THE STATE OF MEDICINE IN ADDICTION RECOVERY

THE STATE OF MEDICINE IN ADDICTION RECOVERY OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,

More information

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information